NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Bayer
K36 Therapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris